Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Secondary Myelodysplastic Syndrome/Acute Myeloblastic Leukemia During Lenalidomide-Based Regimens in Relapsed and/or Refractory Multiple Myeloma Patients: Single Center Experience

Rouslan Kotchetkov, MD, Esther Masih-Khan, PhD, Chia-Min Chu, Young Trieu, Saima Dean, Manjula Maganti, Christine I. Chen, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, MSC, FRCPC, Donna E. Reece, MD, FRCPC

Blood (2012) 120 (21): 1867.

https://doi.org/10.1182/blood.V120.21.1867.1867

Published: 2012

Journal Articles

Prognostic Relevance of Genomic Aberrations In Light Chain Only Multiple Myeloma

Nan Jiang, Connie Qi, Young Trieu, Donna E. Reece, MD, Hong Chang

Blood (2010) 116 (21): 4036.

https://doi.org/10.1182/blood.V116.21.4036.4036

Published: 2010

Journal Articles

Impact of Cytogenetic Abnormalities On Outcome Among Patients with Relapsed/Refractory Multiple Myeloma Treated with Bortezomib: Adverse Effect of 1q21 (CKS1B) Amplification.

Hong Chang, Young Trieu, MSc, Connie Qi, Wei Xu, PhD, Donna E. Reece

Blood (2009) 114 (22): 2826.

https://doi.org/10.1182/blood.V114.22.2826.2826

Published: 2009

Journal Articles

Low Risk of Reactivation of Hepatitis B and Hepatic Injury in Multiple Myeloma (MM) Patients (pts) Undergoing Autologous Stem Cell Transplant (ASCT).

Christine Chen, MD, Young Trieu, MSc, Wei Xu, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Donna E. Reece, MD

Blood (2009) 114 (22): 3345.

https://doi.org/10.1182/blood.V114.22.3345.3345

Published: 2009

Journal Articles

Elderly Multiple Myeloma (MM) Patients (≥70 years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have Shorter Overall Survival Than Younger Patients (<70 years).

Carla Borgono, MSc, PhD, Young Trieu, MSc, Wei Xu, PhD, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Peter Anglin, MD, Christine Chen, MD

Blood (2009) 114 (22): 3409.

https://doi.org/10.1182/blood.V114.22.3409.3409

Published: 2009

Journal Articles

Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.

Donna E. Reece, MD, Faraz Zaman, MD, Young Trieu, MSc, Giovanni Piza Rodriguez, MD, Bruno Teixeira, HBSc, Kim Yoong, BSc, Phm, Fernando Camacho, PhD, Richard K Plante, MSc

Blood (2009) 114 (22): 4892.

https://doi.org/10.1182/blood.V114.22.4892.4892

Published: 2009

Journal Articles

Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.

Donna E. Reece, MD, Young Trieu, MSc, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Wei Xu, PhD, Peter Anglin, MD, Suzanne Trudel, MD

Blood (2009) 114 (22): 1853.

https://doi.org/10.1182/blood.V114.22.1853.1853

Published: 2009

Journal Articles

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

Donna Reece, Kevin W. Song, Tommy Fu, Birgitte Roland, Hong Chang, Douglas E. Horsman, Adnan Mansoor, Christine Chen, Esther Masih-Khan, Young Trieu, Helene Bruyere, Douglas A. Stewart, Nizar J. Bahlis

Blood (2009) 114 (3): 522–525.

https://doi.org/10.1182/blood-2008-12-193458

Published: 2009

Journal Articles

Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.

Donna E. Reece, MD, Young Trieu, MSc, Hong Chang, MD, Wei Xu, PhD, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Joseph Mikhael, MD

Blood (2008) 112 (11): 1724.

https://doi.org/10.1182/blood.V112.11.1724.1724

Published: 2008

Journal Articles

The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.

Nizar J Bahlis, MD, Kevin W. Song, Tommy Fu, Birgitte J Roland, MD, FCCMG, DABMG, Hong Chang, Doug Horsman, MD, PhD, Adnan Mansoor, MD, FRCPC, Christine Chen, MD, Esther Masih- Khan, Young Trieu, MSc, Helene Bruyere, MD, Douglas A. Stewart, MD, FRCPC, Donna E. Reece, MD

Blood (2008) 112 (11): 1731.

https://doi.org/10.1182/blood.V112.11.1731.1731

Published: 2008

Journal Articles

Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)

Anca Prica, MD, Young Trieu, MSc, Wei Xu, PhD, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Peter Anglin, MD, Christine Chen, MD

Blood (2008) 112 (11): 3315.

https://doi.org/10.1182/blood.V112.11.3315.3315

Published: 2008

Journal Articles

Evaluation of Serum Free Light Chains and Outcome in Multiple Myeloma Patients with an Intact Monoclonal Immunoglobulin Treated with Autologous Stem Cell Transplantation.

Young Trieu, Wei Xu, PhD, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Donna E. Reece, MD

Blood (2008) 112 (11): 3323.

https://doi.org/10.1182/blood.V112.11.3323.3323

Published: 2008

Journal Articles

Loss of Chromosome 1p21 Band Is Associated with Disease Progression and Poor Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

Hong Chang, MD, Connie Qi, MD, Allan Jiang, Wei Xu, PhD, Young Trieu, MSc, Donna E. Reece, MD

Blood (2008) 112 (11): 1702.

https://doi.org/10.1182/blood.V112.11.1702.1702

Published: 2008

Journal Articles

Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

Nizar J. Bahlis, MD, Kevin Song, MD, Young Trieu, BS, MS, Birgitte Roland, MD, Esther Masih-Khan, PhD, Hong Chang, MD, Helene Bruyere, MD, Adnan Mansoor, MD, Douglas Horsman, MD, Michael Eliasziw, PhD, Douglas Stewart, MD, Donna Reece, MD

Blood (2007) 110 (11): 3597.

https://doi.org/10.1182/blood.V110.11.3597.3597

Published: 2007

Journal Articles

Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients over Age 70.

Carla Borgono, PhD, Young Trieu, MSc, Wei Xu, PhD, Jacob Pendergrast, MD, Donna Reece, MD, Suzanne Trudel, MD, Joseph Mikhael, MD, Vishal Kukreti, MD, Christine I. Chen, MD

Blood (2007) 110 (11): 4952.

https://doi.org/10.1182/blood.V110.11.4952.4952

Published: 2007

Journal Articles

Effect of the Percent Decrease in Monoclonal Protein with Induction Therapy on the Outcome after Autologous Stem Cell Transplantation in Patients with IgG and IgA Multiple Myeloma.

Donna E. Reece, MD, Young Trieu, M.S., Alida Pokoradi, B.S., Wei Xu, Ph.D., Sharon Fung, M.S., Christine Chen, M.D., Vishal Kukreti, M.D., Joseph Mikhael, M.D., Suzanne Trudel, M.D., A. Keith Stewart, M.D.

Blood (2007) 110 (11): 950.

https://doi.org/10.1182/blood.V110.11.950.950

Published: 2007

Journal Articles

Bortezomib Therapy Response Is Independent of Cytogenetic Abnormalities in Relapsed/Refractory Multiple Myeloma.

Hong Chang, Young Trieu, Xiaoying Qi, Wei Xu, Keith Stewart, Donna Reece

Blood (2006) 108 (11): 5081.

https://doi.org/10.1182/blood.V108.11.5081.5081

Published: 2006

Journal Articles

Weekly Cyclophosphamide and Alternate Day Prednisone: An Effective, Convenient and Well Tolerated Treatment for Relapsed Multiple Myeloma Following Autologous Stem Cell Transplant.

A. Keith Stewart, MD, Young Trieu, MSc, Suzanne Trudel, MD, Greg Pond, MSc, Joseph Mikhael, MD, Donna Reece, MD, Christine Chen, MD

Blood (2004) 104 (11): 4917.

https://doi.org/10.1182/blood.V104.11.4917.4917

Published: 2004

NARROW

Secondary Myelodysplastic Syndrome/Acute Myeloblastic Leukemia During Lenalidomide-Based Regimens in Relapsed and/or Refractory Multiple Myeloma Patients: Single Center Experience

Prognostic Relevance of Genomic Aberrations In Light Chain Only Multiple Myeloma

Impact of Cytogenetic Abnormalities On Outcome Among Patients with Relapsed/Refractory Multiple Myeloma Treated with Bortezomib: Adverse Effect of 1q21 (CKS1B) Amplification.

Low Risk of Reactivation of Hepatitis B and Hepatic Injury in Multiple Myeloma (MM) Patients (pts) Undergoing Autologous Stem Cell Transplant (ASCT).

Elderly Multiple Myeloma (MM) Patients (≥70 years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have Shorter Overall Survival Than Younger Patients (<70 years).

Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.

Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.

The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.

Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)

Evaluation of Serum Free Light Chains and Outcome in Multiple Myeloma Patients with an Intact Monoclonal Immunoglobulin Treated with Autologous Stem Cell Transplantation.

Loss of Chromosome 1p21 Band Is Associated with Disease Progression and Poor Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients over Age 70.

Effect of the Percent Decrease in Monoclonal Protein with Induction Therapy on the Outcome after Autologous Stem Cell Transplantation in Patients with IgG and IgA Multiple Myeloma.

Bortezomib Therapy Response Is Independent of Cytogenetic Abnormalities in Relapsed/Refractory Multiple Myeloma.

Weekly Cyclophosphamide and Alternate Day Prednisone: An Effective, Convenient and Well Tolerated Treatment for Relapsed Multiple Myeloma Following Autologous Stem Cell Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only